Skip to content
2000
Volume 32, Issue 7
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Eugenol, a phenolic phytochemical found in many medicinal plants, exhibits various pharmacological properties, including analgesic, antipyretic, antioxidant, anti-inflammatory, antimicrobial, anticancer, neuroprotective, and anaesthetic effects. It has shown potential in addressing neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease, and motor neuron disease, which are primarily caused by mechanisms such as apoptosis, protein accumulation, aging, and oxidative stress within the central nervous system (CNS). This review explores the mechanisms through which eugenol may influence AD. Eugenol appears to counter oxidative stress, reduce inflammation, and prevent amyloid beta (Aβ) plaque accumulation, suggesting it could delay the onset or progression of AD. However, more research is required to establish its safety and effectiveness in treating or preventing this disease.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128373290250620054118
2025-07-08
2026-03-02

  • From This Site

    /content/journals/cpd/10.2174/0113816128373290250620054118
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. 2023 Alzheimer’s disease facts and figures.Alzheimers Dement.20231941598169510.1002/alz.13016 36918389
     [Google Scholar]
  2. KimD.H. Epidemiology of dementia in korea.Taehan Uihak Hyophoe Chi200245435636010.5124/jkma.2002.45.4.356
     [Google Scholar]
  3. MuckeL. Alzheimer’s disease.Nature2009461726689589710.1038/461895a 19829367
     [Google Scholar]
  4. JansonJ. LaedtkeT. ParisiJ.E. O’BrienP. PetersenR.C. ButlerP.C. Increased risk of type 2 diabetes in Alzheimer disease.Diabetes200453247448110.2337/diabetes.53.2.474 14747300
     [Google Scholar]
  5. BiesselsG.J. StrachanM.W.J. VisserenF.L.J. KappelleL.J. WhitmerR.A. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: Towards targeted interventions.Lancet Diabetes Endocrinol.20142324625510.1016/S2213‑8587(13)70088‑3 24622755
     [Google Scholar]
  6. de la MonteS.M. WandsJ.R. Alzheimer’s disease is type 3 diabetes-evidence reviewed.J. Diabetes Sci. Technol.2008261101111310.1177/193229680800200619 19885299
     [Google Scholar]
  7. PanyS. PalA. SahuP.K. Neuroprotective effect of quercetin in neurotoxicity induced rats: Role of neuroinflammation in neurodegeneration.Asian J. Pharm. Clin. Res.201474152156
     [Google Scholar]
  8. SarkarA. GogiaN. GlennN. A soy protein lunasin can ameliorate amyloid-beta 42 mediated neurodegeneration in drosophila eye.Sci. Rep.2018811354510.1038/s41598‑018‑31787‑7 30202077
     [Google Scholar]
  9. WilliamsP. SorribasA. HowesM.J.R. Natural products as a source of Alzheimer’s drug leads.Nat. Prod. Rep.2011281487710.1039/C0NP00027B 21072430
     [Google Scholar]
  10. ZhangH.Y. ZhengC.Y. YanH. Potential therapeutic targets of huperzine A for Alzheimer’s disease and vascular dementia.Chem. Biol. Interact.20081751-339640210.1016/j.cbi.2008.04.049 18565502
     [Google Scholar]
  11. PisanoM. PagnanG. LoiM. Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells.Mol. Cancer200761810.1186/1476‑4598‑6‑8 17233906
     [Google Scholar]
  12. Kar MahapatraS. ChakrabortyS.P. MajumdarS. BagB.G. RoyS. Eugenol protects nicotine-induced superoxide mediated oxidative damage in murine peritoneal macrophages in vitro.Eur. J. Pharmacol.20096231-313214010.1016/j.ejphar.2009.09.019 19769960
     [Google Scholar]
  13. YogalakshmiB. ViswanathanP. AnuradhaC.V. Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats.Toxicology2010268320421210.1016/j.tox.2009.12.018 20036707
     [Google Scholar]
  14. TaoG. IrieY. LiD.J. KeungW.M. Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity.Bioorg. Med. Chem.200513154777478810.1016/j.bmc.2005.04.081 15936201
     [Google Scholar]
  15. IrieY. ItokazuN. AnjikiN. IshigeA. WatanabeK. KeungW.M. Eugenol exhibits antidepressant-like activity in mice and induces expression of metallothionein-III in the hippocampus.Brain Res.20041011224324610.1016/j.brainres.2004.03.040 15157811
     [Google Scholar]
  16. AhrensC.H. BrunnerE. BaslerK. Quantitative proteomics: A central technology for systems biology.J. Proteomics201073482082710.1016/j.jprot.2009.12.007 20026292
     [Google Scholar]
  17. ChristenY. Oxidative stress and Alzheimer disease.Am. J. Clin. Nutr.2000712621S629S10.1093/ajcn/71.2.621s 10681270
     [Google Scholar]
  18. KozlowskiH. Janicka-KlosA. BrasunJ. GaggelliE. ValensinD. ValensinG. Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation).Coord. Chem. Rev.200925321-222665268510.1016/j.ccr.2009.05.011
     [Google Scholar]
  19. BarnhamK.J. McKinstryW.J. MulthaupG. Structure of the Alzheimer’s disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis.J. Biol. Chem.200327819174011740710.1074/jbc.M300629200 12611883
     [Google Scholar]
  20. MiuraT. SuzukiK. KohataN. TakeuchiH. Metal binding modes of Alzheimer’s amyloid β-peptide in insoluble aggregates and soluble complexes.Biochemistry200039237024703110.1021/bi0002479 10841784
     [Google Scholar]
  21. StrozykD. LaunerL.J. AdlardP.A. Zinc and copper modulate Alzheimer Aβ levels in human cerebrospinal fluid.Neurobiol. Aging20093071069107710.1016/j.neurobiolaging.2007.10.012 18068270
     [Google Scholar]
  22. ValkoM. MorrisH. CroninM. Metals, toxicity and oxidative stress.Curr. Med. Chem.200512101161120810.2174/0929867053764635 15892631
     [Google Scholar]
  23. Allan ButterfieldD. Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer’s disease brain. A review.Free Radic. Res.200236121307131310.1080/1071576021000049890 12607822
     [Google Scholar]
  24. ChowdhuryS. KumarS. Inhibition of BACE1, MAO-B, cholinesterase enzymes, and anti-amyloidogenic potential of selected natural phytoconstituents: Multi-target-directed ligand approach.J. Food Biochem.2021451e1357110.1111/jfbc.13571 33249607
     [Google Scholar]
  25. AdefeghaS.A. OkekeB.M. ObohG. Antioxidant properties of eugenol, butylated hydroxylanisole, and butylated hydroxyl toluene with key biomolecules relevant to Alzheimer’s diseases—in vitro.J. Food Biochem.2021453e1327610.1111/jfbc.13276 32458455
     [Google Scholar]
  26. KumarA. SiddiqiN.J. AlrashoodS.T. KhanH.A. DubeyA. SharmaB. Protective effect of eugenol on hepatic inflammation and oxidative stress induced by cadmium in male rats.Biomed. Pharmacother.202113911158810.1016/j.biopha.2021.111588 33862491
     [Google Scholar]
  27. MesoleS.B. AlfredO.O. YusufU.A. LukubiL. NdhlovuD. Apoptotic inducement of neuronal cells by aluminium chloride and the neuroprotective effect of eugenol in wistar rats.Oxid. Med. Cell. Longev.202020201710.1155/2020/8425643 32089784
     [Google Scholar]
  28. HuangX. MoirR.D. TanziR. BushA. RogersJ.T. Redox-active metals, oxidative stress, and Alzheimer’s disease pathology.Ann. N. Y. Acad. Sci.20041012115316310.1196/annals.1306.012 15105262
     [Google Scholar]
  29. CuajungcoM.P. FagétK.Y. Zinc takes the center stage: Its paradoxical role in Alzheimer’s disease.Brain Res. Brain Res. Rev.2003411445610.1016/S0165‑0173(02)00219‑9 12505647
     [Google Scholar]
  30. PalA. BadyalR.K. VasishtaR.K. AttriS.V. ThapaB.R. PrasadR. Biochemical, histological, and memory impairment effects of chronic copper toxicity: A model for non-Wilsonian brain copper toxicosis in Wistar rat.Biol. Trace Elem. Res.20131531-325726810.1007/s12011‑013‑9665‑0 23613148
     [Google Scholar]
  31. MarkesberyW.R. Oxidative stress hypothesis in Alzheimer’s disease.Free Radic. Biol. Med.199723113414710.1016/S0891‑5849(96)00629‑6 9165306
     [Google Scholar]
  32. TsaluchiduS. CocchiM. TonelloL. PuriB.K. Fatty acids and oxidative stress in psychiatric disorders.BMC Psychiatry20088S1S510.1186/1471‑244X‑8‑S1‑S5 18433515
     [Google Scholar]
  33. ButterfieldD.A. HensleyK. ColeP. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: Relevance to Alzheimer’s disease.J. Neurochem.19976862451245710.1046/j.1471‑4159.1997.68062451.x 9166739
     [Google Scholar]
  34. MoreiraP. HondaK. LiuQ. Alzheimer’s disease and oxidative stress: The old problem remains unsolved.Curr. Med. Chem. Cent. Nerv. Syst. Agents200551516210.2174/1568015053202714
     [Google Scholar]
  35. KooE.H. LansburyP.T. KellyJ.W. Amyloid diseases: Abnormal protein aggregation in neurodegeneration.Proc. Natl. Acad. Sci. USA199996189989999010.1073/pnas.96.18.9989 10468546
     [Google Scholar]
  36. MarkesberyW.R. The role of oxidative stress in Alzheimer disease.Arch. Neurol.199956121449145210.1001/archneur.56.12.1449 10593298
     [Google Scholar]
  37. AnneB. DawnayandS.J. MillarD.J. Glycation and advanced glycation end-product formation with icodextrin and dextrose.Perit. Dial. Int.1997171525810.1177/089686089701700112 9068023
     [Google Scholar]
  38. CookeM.S. EvansM.D. DizdarogluM. LunecJ. Oxidative DNA damage: Mechanisms, mutation, and disease.FASEB J.200317101195121410.1096/fj.02‑0752rev 12832285
     [Google Scholar]
  39. WojsiatJ. Laskowska-KaszubK. Mietelska-PorowskaA. WojdaU. Search for Alzheimer’s disease biomarkers in blood cells: Hypotheses-driven approach.Biomarkers Med.2017111091793110.2217/bmm‑2017‑0041 28976776
     [Google Scholar]
  40. AngiulliF. ContiE. ZoiaC.P. Blood-based biomarkers of neuroinflammation in Alzheimer’s disease: A central role for periphery?Diagnostics (Basel)2021119152510.3390/diagnostics11091525 34573867
     [Google Scholar]
  41. KhanT.K. AlkonD.L. Peripheral biomarkers of Alzheimer’s disease.J. Alzheimers Dis.201544372974410.3233/JAD‑142262 25374110
     [Google Scholar]
  42. WojdaU. Alzheimer’s disease lymphocytes: Potential for biomarkers?Biomarkers Med.20161011410.2217/bmm.15.79 26640978
     [Google Scholar]
  43. WojsiatJ. PrandelliC. Laskowska-KaszubK. Martín-RequeroA. WojdaU. Oxidative stress and aberrant cell cycle in Alzheimer’s disease lymphocytes: Diagnostic prospects.J. Alzheimers Dis.201546232935010.3233/JAD‑141977 25737047
     [Google Scholar]
  44. LeutnerS. SchindowskiK. FrölichL. Enhanced ROS-generation in lymphocytes from Alzheimer’s patients.Pharmacopsychiatry200538631231510.1055/s‑2005‑916186 16342003
     [Google Scholar]
  45. CalabreseV. SultanaR. ScapagniniG. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer’s disease.Antioxid. Redox Signal.2006811-121975198610.1089/ars.2006.8.1975 17034343
     [Google Scholar]
  46. SkoumalováA. IvicaJ. ŠantorováP. TopinkováE. WilhelmJ. The lipid peroxidation products as possible markers of Alzheimer’s disease in blood.Exp. Gerontol.2011461384210.1016/j.exger.2010.09.015 20920571
     [Google Scholar]
  47. BuizzaL. CeniniG. LanniC. Conformational altered p53 as an early marker of oxidative stress in Alzheimer’s disease.PLoS One201271e2978910.1371/journal.pone.0029789 22242180
     [Google Scholar]
  48. NunomuraA. PerryG. AlievG. Oxidative damage is the earliest event in Alzheimer disease.J. Neuropathol. Exp. Neurol.200160875976710.1093/jnen/60.8.759 11487050
     [Google Scholar]
  49. NunomuraA. CastellaniR.J. ZhuX. MoreiraP.I. PerryG. SmithM.A. Involvement of oxidative stress in Alzheimer disease.J. Neuropathol. Exp. Neurol.200665763164110.1097/01.jnen.0000228136.58062.bf 16825950
     [Google Scholar]
  50. KadiogluE. SardasS. AslanS. IsikE. KarakayaA.E. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer’s disease.Biomarkers20049220320910.1080/13547500410001728390 15370876
     [Google Scholar]
  51. MóroczM. KálmánJ. JuhászA. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer’s disease.Neurobiol. Aging20022314753 11755018
     [Google Scholar]
  52. Gulec PekerE.G. KaltaliogluK. Cinnamaldehyde and eugenol protect against LPS-stimulated oxidative stress and inflammation in Raw 264.7 cells.J. Food Biochem.20214512e1398010.1111/jfbc.13980 34676584
     [Google Scholar]
  53. KabutoH. TadaM. KohnoM. Eugenol [2-methoxy-4-(2-propenyl)phenol] prevents 6-hydroxydopamine-induced dopamine depression and lipid peroxidation inductivity in mouse striatum.Biol. Pharm. Bull.200730342342710.1248/bpb.30.423 17329831
     [Google Scholar]
  54. KhalilA.A. RahmanU. KhanM.R. SaharA. MehmoodT. KhanM. Essential oil eugenol: Sources, extraction techniques and nutraceutical perspectives.RSC Advances2017752326693268110.1039/C7RA04803C
     [Google Scholar]
  55. TammannavarP.C.P. JainS. SvS. An unexpected positive hypersensitive reaction to eugenol.BMJ Case Rep.20132013bcr201300946410.1136/bcr‑2013‑009464 24049087
     [Google Scholar]
  56. Tavvabi-KashaniN. HasanpourM. Baradaran RahimiV. Vahdati-MashhadianN. AskariV.R. Pharmacodynamic, pharmacokinetic, toxicity, and recent advances in Eugenol’s potential benefits against natural and chemical noxious agents: A mechanistic review.Toxicon202423810760710.1016/j.toxicon.2024.107607 38191032
     [Google Scholar]
  57. Gülçinİ. Antioxidant activity of eugenol: A structure-activity relationship study.J. Med. Food201114997598510.1089/jmf.2010.0197 21554120
     [Google Scholar]
  58. Pérez-RosésR. RiscoE. VilaR. PeñalverP. CañigueralS. Biological and nonbiological antioxidant activity of some essential oils.J. Agric. Food Chem.201664234716472410.1021/acs.jafc.6b00986 27214068
     [Google Scholar]
  59. Charan RajaM.R. Versatile and synergistic potential of eugenol: A review.Pharm. Anal. Acta2015651610.4172/2153‑2435.1000367
     [Google Scholar]
  60. FathyM. FawzyM.A. HintzscheH. NikaidoT. DandekarT. OthmanE.M. Eugenol exerts apoptotic effect and modulates the sensitivity of HeLa cells to cisplatin and radiation.Molecules20192421397910.3390/molecules24213979 31684176
     [Google Scholar]
  61. Mohammadi NejadS. ÖzgüneşH. BaşaranN. Pharmacological and toxicological properties of eugenol.Turk J Pharm Sci201714220120610.4274/tjps.62207 32454614
     [Google Scholar]
  62. KuhlaB. LüthH.J. HaferburgD. BoeckK. ArendtT. MünchG. Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease.Ann. N. Y. Acad. Sci.20051043121121610.1196/annals.1333.026 16037241
     [Google Scholar]
  63. LüthH.J. MünchG. ArendtT. Aberrant expression of NOS isoforms in Alzheimer’s disease is structurally related to nitrotyrosine formation.Brain Res.20029531-213514310.1016/S0006‑8993(02)03280‑8 12384247
     [Google Scholar]
  64. LüthH.J. OgunladeV. KuhlaB. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer’s disease brains.Cereb. Cortex200415221122010.1093/cercor/bhh123 15238435
     [Google Scholar]
  65. MünchG. SchinzelR. LoskeC. Alzheimer’s disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts.J. Neural Transm.1998105443946110.1007/s007020050069 9720973
     [Google Scholar]
  66. RetzW. GsellW. MünchG. RöslerM. RiedererP. Free radicals in Alzheimer’s disease.Alzheimer’s disease — From basic research to clinical applications. GertzH.J. ArendtTh. ViennaSpringer199822123610.1007/978‑3‑7091‑7508‑8_22
     [Google Scholar]
  67. ReviN. RenganA.K. Eugenol-encapsulated nanocarriers for microglial polarisation: A promising therapeutic application for neuroprotection.Bionanoscience20201041010101710.1007/s12668‑020‑00789‑z
     [Google Scholar]
  68. VenegasC. HenekaM.T. Danger-associated molecular patterns in Alzheimer’s disease.J. Leukoc. Biol.20171011879810.1189/jlb.3MR0416‑204R 28049142
     [Google Scholar]
  69. LeeJ. HongS. AhnM. Eugenol alleviates the symptoms of experimental autoimmune encephalomyelitis in mice by suppressing inflammatory responses.Int. Immunopharmacol.202412811147910.1016/j.intimp.2023.111479 38215654
     [Google Scholar]
  70. CagninA. GerhardA. BanatiR.B. The concept of in vivo imaging of neuroinflammation with [11C](R)-PK11195 PET.Ernst Schering Res200220023917919110.1007/978‑3‑662‑05073‑6_10 12066412
     [Google Scholar]
  71. VersijptJ.J. DumontF. van LaereK.J. Assessment of neuroinflammation and microglial activation in Alzheimer’s disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study.Eur. Neurol.2003501394710.1159/000070857 12824711
     [Google Scholar]
  72. BettensK. SleegersK. Van BroeckhovenC. Genetic insights in Alzheimer’s disease.Lancet Neurol.20131219210410.1016/S1474‑4422(12)70259‑4 23237904
     [Google Scholar]
  73. BreitnerJ.C. BakerL.D. MontineT.J. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial.Alzheimers Dement.20117440241110.1016/j.jalz.2010.12.014 21784351
     [Google Scholar]
  74. BlockM.L. ZeccaL. HongJ.S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms.Nat. Rev. Neurosci.200781576910.1038/nrn2038 17180163
     [Google Scholar]
  75. FujisawaS. MurakamiY. Eugenol and its role in chronic diseases.Adv. Exp. Med. Biol.2016929456610.1007/978‑3‑319‑41342‑6_3 27771920
     [Google Scholar]
  76. JaganathanS.K. SupriyantoE. Antiproliferative and molecular mechanism of eugenol-induced apoptosis in cancer cells.Molecules20121766290630410.3390/molecules17066290 22634840
     [Google Scholar]
  77. PezzaniR. SalehiB. VitaliniS. Synergistic effects of plant derivatives and conventional chemotherapeutic agents: An update on the cancer perspective.Medicina (Kaunas)201955411010.3390/medicina55040110 30999703
     [Google Scholar]
  78. ZhangY. LiangX. BaoX. XiaoW. ChenG. Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective.Eur. J. Med. Chem.202223511429110.1016/j.ejmech.2022.114291 35307617
     [Google Scholar]
  79. ZhuJ. ParkS. KimC.H. JeongK.H. KimW.J. Eugenol alleviates neuronal damage via inhibiting inflammatory process against pilocarpine-induced status epilepticus.Exp. Biol. Med. (Maywood)2023248872273110.1177/15353702231151976 36802956
     [Google Scholar]
  80. HuangJ.J. FengY.M. ZhengS.M. Eugenol possesses colitis protective effects: Impacts on the TLR4/MyD88/NF-κB pathway, intestinal epithelial barrier, and macrophage polarization.Am. J. Chin. Med.202452249351210.1142/S0192415X24500216 38480500
     [Google Scholar]
  81. MaQ. KinneerK. Chemoprotection by phenolic antioxidants. Inhibition of tumor necrosis factor α induction in macrophages.J. Biol. Chem.200227742477248410.1074/jbc.M106685200 11694529
     [Google Scholar]
  82. MurakamiY. ShojiM. HanazawaS. TanakaS. FujisawaS. Preventive effect of bis -eugenol, a eugenol ortho dimer, on lipopolysaccharide-stimulated nuclear factor kappa B activation and inflammatory cytokine expression in macrophages.Biochem. Pharmacol.20036661061106610.1016/S0006‑2952(03)00419‑2 12963494
     [Google Scholar]
  83. MurakamiY. ShojiM. HirataA. TanakaS. YokoeI. FujisawaS. Dehydrodiisoeugenol, an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages.Arch. Biochem. Biophys.2005434232633210.1016/j.abb.2004.11.013 15639233
     [Google Scholar]
  84. HuangX. LiuY. LuY. MaC. Anti-inflammatory effects of eugenol on lipopolysaccharide-induced inflammatory reaction in acute lung injury via regulating inflammation and redox status.Int. Immunopharmacol.201526126527110.1016/j.intimp.2015.03.026 25863235
     [Google Scholar]
  85. OrbanJ.C. WalraveY. MongardonN. Causes and characteristics of death in intensive care units: A prospective multicenter study.Anesthesiology2017126588288910.1097/ALN.0000000000001612 28296682
     [Google Scholar]
  86. MagalhãesC.B. CasquilhoN.V. MachadoM.N. The anti-inflammatory and anti-oxidative actions of eugenol improve lipopolysaccharide-induced lung injury.Respir. Physiol. Neurobiol.2019259303610.1016/j.resp.2018.07.001 29997055
     [Google Scholar]
  87. GrespanR. PaludoM. LemosH.P. Anti-arthritic effect of eugenol on collagen-induced arthritis experimental model.Biol. Pharm. Bull.201235101818182010.1248/bpb.b12‑00128 23037170
     [Google Scholar]
  88. BarbozaJ.N. da Silva Maia Bezerra FilhoC. SilvaR.O. MedeirosJ.V.R. de SousaD.P. An overview on the anti-inflammatory potential and antioxidant profile of eugenol.Oxid. Med. Cell. Longev.201820181395726210.1155/2018/3957262 30425782
     [Google Scholar]
  89. EsmaeiliF. RajabnejhadS. PartoazarA.R. Anti-inflammatory effects of eugenol nanoemulsion as a topical delivery system.Pharm. Dev. Technol.201621788789310.3109/10837450.2015.1078353 26365132
     [Google Scholar]
  90. BalkrishnaA. SolletiS.K. SinghH. TomerM. SharmaN. VarshneyA. Calcio-herbal formulation, Divya-Swasari-Ras, alleviates chronic inflammation and suppresses airway remodelling in mouse model of allergic asthma by modulating pro-inflammatory cytokine response.Biomed. Pharmacother.202012611006310.1016/j.biopha.2020.110063 32145582
     [Google Scholar]
  91. CilbertiM.G. SantilloA. PolitoA.N. Cytokine pattern of peripheral blood mononuclear cells isolated from children affected by generalized epilepsy treated with different protein fractions of meat sources.Nutrients20221411224310.3390/nu14112243 35684043
     [Google Scholar]
  92. HobaniY.H. MohanS. ShaheenE. Gastroprotective effect of low dose Eugenol in experimental rats against ethanol induced toxicity: Involvement of antiinflammatory and antioxidant mechanism.J. Ethnopharmacol.202228911505510.1016/j.jep.2022.115055 35101571
     [Google Scholar]
  93. ReuterS. GuptaS.C. ChaturvediM.M. AggarwalB.B. Oxidative stress, inflammation, and cancer: How are they linked?Free Radic. Biol. Med.201049111603161610.1016/j.freeradbiomed.2010.09.006 20840865
     [Google Scholar]
  94. CuiZ. LiuZ. ZengJ. Eugenol inhibits non-small cell lung cancer by repressing expression of NF-κB-regulated TRIM59.Phytother. Res.20193351562156910.1002/ptr.6352 30932261
     [Google Scholar]
  95. DamascenoR.O.S. PinheiroJ.L.S. RodriguesL.H.M. Anti-inflammatory and antioxidant activities of eugenol: An update.Pharmaceuticals20241711150510.3390/ph17111505 39598416
     [Google Scholar]
  96. PadhyI. PaulP. SharmaT. BanerjeeS. MondalA. Molecular mechanisms of action of eugenol in cancer: Recent trends and advancement.Life20221211179510.3390/life12111795 36362950
     [Google Scholar]
  97. HuiQ. AmmeterE. LiuS. Eugenol attenuates inflammatory response and enhances barrier function during lipopolysaccharide-induced inflammation in the porcine intestinal epithelial cells.J. Anim. Sci.2020988skaa24510.1093/jas/skaa245 32735667
     [Google Scholar]
  98. MedzhitovR. Origin and physiological roles of inflammation.Nature2008454720342843510.1038/nature07201 18650913
     [Google Scholar]
  99. Ferrero-MilianiL. NielsenO.H. AndersenP.S. GirardinS.E. Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1β generation.Clin. Exp. Immunol.2007147222723510.1111/j.1365‑2249.2006.03261.x 17223962
     [Google Scholar]
  100. SaraivaR.A. ArarunaM.K.A. OliveiraR.C. Topical anti-inflammatory effect of Caryocar coriaceum Wittm. (Caryocaraceae) fruit pulp fixed oil on mice ear edema induced by different irritant agents.J. Ethnopharmacol.2011136350451010.1016/j.jep.2010.07.002 20621180
     [Google Scholar]
  101. AyalaA. MuñozM.F. ArgüellesS. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal.Oxid. Med. Cell. Longev.20142014113110.1155/2014/360438 24999379
     [Google Scholar]
  102. KaurG. AtharM. AlamM.S. Eugenol precludes cutaneous chemical carcinogenesis in mouse by preventing oxidative stress and inflammation and by inducing apoptosis.Mol. Carcinog.201049329030110.1002/mc.20601 20043298
     [Google Scholar]
  103. MagalhãesC.B. RivaD.R. DePaulaL.J. In vivo anti-inflammatory action of eugenol on lipopolysaccharide-induced lung injury.J. Appl. Physiol.2010108484585110.1152/japplphysiol.00560.2009 20075264
     [Google Scholar]
  104. PatlevičP. VaškováJ. ŠvorcP. VaškoL. ŠvorcP. Reactive oxygen species and antioxidant defense in human gastrointestinal diseases.Integr. Med. Res.20165425025810.1016/j.imr.2016.07.004 28462126
     [Google Scholar]
  105. HaassC. HungA.Y. SelkoeD.J. Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion.J. Neurosci.199111123783379310.1523/JNEUROSCI.11‑12‑03783.1991 1744690
     [Google Scholar]
  106. KangJ. LemaireH.G. UnterbeckA. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor.Nature1987325610673373610.1038/325733a0 2881207
     [Google Scholar]
  107. VassarR. BennettB.D. Babu-KhanS. β-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE.Science1999286544073574110.1126/science.286.5440.735 10531052
     [Google Scholar]
  108. IbenL.G. KopchoL. MarcinkevicieneJ. [3H]BMS-599240 - A novel tritiated ligand for the characterization of BACE1 inhibitors.Eur. J. Pharmacol.20085931-3101510.1016/j.ejphar.2008.06.112 18655784
     [Google Scholar]
  109. MoghekarA. RaoS. LiM. Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro.J. Biol. Chem.201128618159891599710.1074/jbc.M110.191262 21454701
     [Google Scholar]
  110. BusciglioJ. GabuzdaD.H. MatsudairaP. YanknerB.A. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells.Proc. Natl. Acad. Sci. USA19939052092209610.1073/pnas.90.5.2092 8446635
     [Google Scholar]
  111. ChenM. InestrosaN.C. RossG.S. FernandezH.L. Platelets are the primary source of amyloid β-peptide in human blood.Biochem. Biophys. Res. Commun.199521319610310.1006/bbrc.1995.2103 7639768
     [Google Scholar]
  112. AwasthiM. SinghS. PandeyV.P. DwivediU.N. Alzheimer’s disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products.J. Neurol. Sci.201636125627110.1016/j.jns.2016.01.008 26810552
     [Google Scholar]
  113. RajasekharK. ChakrabartiM. GovindarajuT. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer’s disease.Chem. Commun. (Camb.)20155170134341345010.1039/C5CC05264E 26247608
     [Google Scholar]
  114. PaganoK. TomaselliS. MolinariH. RagonaL. Natural compounds as inhibitors of Aβ peptide aggregation: Chemical requirements and molecular mechanisms.Front. Neurosci.20201461966710.3389/fnins.2020.619667 33414705
     [Google Scholar]
  115. CheignonC. TomasM. Bonnefont-RousselotD. FallerP. HureauC. CollinF. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease.Redox Biol.20181445046410.1016/j.redox.2017.10.014 29080524
     [Google Scholar]
  116. CulibrkR.A. HahnM.S. The role of chronic inflammatory bone and joint disorders in the pathogenesis and progression of Alzheimer’s disease.Front. Aging Neurosci.20201258388410.3389/fnagi.2020.583884 33364931
     [Google Scholar]
  117. TaheriP. YaghmaeiP. TehraniH.S. Ebrahim-HabibiA. Effects of eugenol on Alzheimer’s disease-like manifestations in insulin-and Aβ-induced rat models.Neurophysiology201951211411910.1007/s11062‑019‑09801‑z
     [Google Scholar]
  118. GoyalA. SolankiA. VermaA. Preclinical evidence-based review on therapeutic potential of eugenol for the treatment of brain disorders.Curr. Mol. Med.202323539040010.2174/1566524022666220525145521 35619280
     [Google Scholar]
  119. AnujG. SanjayS. Eugenol: A potential phytochemical with multifaceted therapeutic activities.Pharmacologyonline20102108120
     [Google Scholar]
  120. Moreira VasconcelosC.F. da Cunha FerreiraN.M. Hardy Lima PontesN. Eugenol and its association with levodopa in 6-hydroxydopamine-induced hemiparkinsonian rats: Behavioural and neurochemical alterations.Basic Clin. Pharmacol. Toxicol.2020127428730210.1111/bcpt.13425 32353201
     [Google Scholar]
  121. PrasadS.N. Muralidhara Neuroprotective efficacy of eugenol and isoeugenol in acrylamide-induced neuropathy in rats: Behavioral and biochemical evidence.Neurochem. Res.201338233034510.1007/s11064‑012‑0924‑9 23161090
     [Google Scholar]
  122. PrasadS.N. Muralidhara Evidence of acrylamide induced oxidative stress and neurotoxicity in Drosophila melanogaster - Its amelioration with spice active enrichment: Relevance to neuropathy.Neurotoxicology20123351254126410.1016/j.neuro.2012.07.006 22841601
     [Google Scholar]
  123. GarabaduD. ShahA. AhmadA. Eugenol as an anti-stress agent: Modulation of hypothalamic-pituitary-adrenal axis and brain monoaminergic systems in a rat model of stress.Stress201114214515510.3109/10253890.2010.521602 21034296
     [Google Scholar]
  124. IrieY. Effects of eugenol on the central nervous system: Its possible application to treatment of Alzheimer’s disease, depression, and parkinson’s disease.Curr. Bioact. Compd.200621576610.2174/1573407210602010057
     [Google Scholar]
  125. IrieY. KeungW.M. Rhizoma acori gramineiand its active principles protect PC-12 cells from the toxic effect of amyloid-β peptide.Brain Res.20039631-228228910.1016/S0006‑8993(02)04050‑7 12560134
     [Google Scholar]
  126. MüllerM. PapeH.C. SpeckmannE.J. GorjiA. Effect of eugenol on spreading depression and epileptiform discharges in rat neocortical and hippocampal tissues.Neuroscience2006140274375110.1016/j.neuroscience.2006.02.036 16563641
     [Google Scholar]
  127. YazakiK. Study of behavioral pharmacology on rats. Tranquilizing effects induced by endogenous or exogenous bradykinin.Shikwa Gakuho1989891015291548 2488972
     [Google Scholar]
  128. GarabaduD. ShahA. SinghS. KrishnamurthyS. Protective effect of eugenol against restraint stress-induced gastrointestinal dysfunction: Potential use in irritable bowel syndrome.Pharm. Biol.201553796897410.3109/13880209.2014.950674 25473818
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128373290250620054118
Loading
Neuroprotective Effects of Eugenol in Alzheimer's Disease: Mitigating Oxidative Stress, Inflammation and Amyloid Plaques
Curr. Pharm. Des. 32, 493 (2026); https://doi.org/10.2174/0113816128373290250620054118
/content/journals/cpd/10.2174/0113816128373290250620054118
/content/journals/cpd/10.2174/0113816128373290250620054118
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alzheimer’s disease; anti-inflammatory; antioxidant; Eugenol; neurodegenerative disorders; pharmacological properties

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test